NextCell Pharma AB Cash Flow-to-Debt Ratio
NextCell Pharma AB cash flow-to-debt ratio. NextCell Pharma AB (NXTCL) has a Cash Flow-to-Debt Ratio of -1.04x as of August 2025, meaning its operating cash flow of Skr-10.77 Million could theoretically repay -1% of its total liabilities (Skr10.34 Million) in one year. See NXTCL financial flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of NextCell Pharma AB (2015–2025)
Cash flow-to-debt ratio of NextCell Pharma AB from 2015 to 2025. Historical debt coverage capacity for NextCell Pharma AB across 11 annual periods. Also explore NXTCL net asset momentum to track the company's year-over-year net asset growth rate.
NextCell Pharma AB Cash Flow-to-Debt Ratio by Year (2015–2025)
NextCell Pharma AB cash flow-to-debt ratio by year from 2015 to 2025. Year-by-year debt coverage analysis for NextCell Pharma AB. For the full cash flow conversion analysis, see NXTCL cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (SEK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.76x | Skr-38.86 Million | Skr10.34 Million | ▼ -36.1% |
| 2024 | -2.76x | Skr-37.78 Million | Skr13.69 Million | ▲ +17.5% |
| 2023 | -3.35x | Skr-43.83 Million | Skr13.10 Million | ▲ +8.4% |
| 2022 | -3.65x | Skr-33.31 Million | Skr9.12 Million | ▲ +20.9% |
| 2021 | -4.62x | Skr-25.58 Million | Skr5.53 Million | ▲ +13.3% |
| 2020 | -5.33x | Skr-18.96 Million | Skr3.56 Million | ▲ +9.5% |
| 2019 | -5.89x | Skr-22.13 Million | Skr3.76 Million | ▼ -50.8% |
| 2018 | -3.91x | Skr-13.55 Million | Skr3.47 Million | ▲ +32.7% |
| 2017 | -5.80x | Skr-14.82 Million | Skr2.55 Million | ▼ -41.0% |
| 2016 | -4.12x | Skr-11.12 Million | Skr2.70 Million | ▼ -37.2% |
| 2015 | -3.00x | Skr-7.76 Million | Skr2.59 Million | — |